Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

6(85.7%)

Phase 2

1(14.3%)

7Total

Phase 1(6)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07284485Phase 2Recruiting

Immunoprevention for High-risk Lung Lesions

Role: collaborator

NCT07281716Phase 1Recruiting

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

Role: collaborator

NCT05181462Phase 1Active Not Recruiting

Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.

Role: lead

NCT03267316Phase 1Completed

A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

Role: lead

NCT04452214Phase 1Completed

A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

Role: lead

NCT05116891Phase 1Completed

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Role: lead

NCT04990037Phase 1Completed

A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Role: lead

All 7 trials loaded